Cargando…

We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity

Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutta, Nirjhar, Ingraham, Nicholas E., Usher, Michael G., Fox, Claudia, Tignanelli, Christopher J., Bramante, Carolyn T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930643/
https://www.ncbi.nlm.nih.gov/pubmed/33648370
http://dx.doi.org/10.1177/2150132721996283
_version_ 1783660138830233600
author Dutta, Nirjhar
Ingraham, Nicholas E.
Usher, Michael G.
Fox, Claudia
Tignanelli, Christopher J.
Bramante, Carolyn T.
author_facet Dutta, Nirjhar
Ingraham, Nicholas E.
Usher, Michael G.
Fox, Claudia
Tignanelli, Christopher J.
Bramante, Carolyn T.
author_sort Dutta, Nirjhar
collection PubMed
description Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France show odds ratio (OR) of 2.31 (95% CI 1.3-4.1) for obesity and severe COVID-19. Other studies show OR of 12.1 (95% CI 3.25-45.1) for mortality and OR of 7.36 (95% CI 1.63-33.14) for need for IMV for patients with body mass index (BMI) ≥ 35 kg/m(2). Obesity is the only modifiable risk factor that is not routinely treated but treatment can lead to improvement in visceral adiposity, insulin sensitivity, and mortality risk. Increasing the awareness of the association between obesity and COVID-19 risk in the general population and medical community may serve as the impetus to make obesity identification and management a higher priority.
format Online
Article
Text
id pubmed-7930643
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79306432021-03-12 We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity Dutta, Nirjhar Ingraham, Nicholas E. Usher, Michael G. Fox, Claudia Tignanelli, Christopher J. Bramante, Carolyn T. J Prim Care Community Health Commentaries Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France show odds ratio (OR) of 2.31 (95% CI 1.3-4.1) for obesity and severe COVID-19. Other studies show OR of 12.1 (95% CI 3.25-45.1) for mortality and OR of 7.36 (95% CI 1.63-33.14) for need for IMV for patients with body mass index (BMI) ≥ 35 kg/m(2). Obesity is the only modifiable risk factor that is not routinely treated but treatment can lead to improvement in visceral adiposity, insulin sensitivity, and mortality risk. Increasing the awareness of the association between obesity and COVID-19 risk in the general population and medical community may serve as the impetus to make obesity identification and management a higher priority. SAGE Publications 2021-03-01 /pmc/articles/PMC7930643/ /pubmed/33648370 http://dx.doi.org/10.1177/2150132721996283 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Commentaries
Dutta, Nirjhar
Ingraham, Nicholas E.
Usher, Michael G.
Fox, Claudia
Tignanelli, Christopher J.
Bramante, Carolyn T.
We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
title We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
title_full We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
title_fullStr We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
title_full_unstemmed We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
title_short We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
title_sort we should do more to offer evidence-based treatment for an important modifiable risk factor for covid-19: obesity
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930643/
https://www.ncbi.nlm.nih.gov/pubmed/33648370
http://dx.doi.org/10.1177/2150132721996283
work_keys_str_mv AT duttanirjhar weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity
AT ingrahamnicholase weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity
AT ushermichaelg weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity
AT foxclaudia weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity
AT tignanellichristopherj weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity
AT bramantecarolynt weshoulddomoretoofferevidencebasedtreatmentforanimportantmodifiableriskfactorforcovid19obesity